

**EFC17574: A Phase 3, single-arm, multicenter, multinational, open label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged  $\geq$  12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX**

**Status:** Recruiting

## Eligibility Criteria

**Sex:** Male

**Age Group:** Not specified

This study is NOT accepting healthy volunteers

### Inclusion Criteria:

- 12 years or older - diagnosis of severe congenital hemophilia A or B - participants currently not on prophylaxis (CFC or BPA on-demand): A minimum of 4 bleeding episodes requiring BPA (inhibitor participants) or CFC (non-inhibitor participants) treatment within the last 6 months

---

### Exclusion Criteria:

- co-existing bleeding disorders other than congenital hemophilia A or B - current participation in immune tolerance induction therapy (ITI) - prior treatment with gene therapy - acute hepatitis, ie, hepatitis A, hepatitis E, acute or chronic hepatitis B infection - additional exclusion criteria apply (study staff will review)

## Conditions & Interventions

### Conditions:

Blood Disorders

### Keywords:

Hemophilia

## More Information

**Description:** A study to test a medicine (fitusiran) injected under the skin for preventing bleeding episodes in male adolescent or adult participants with severe Hemophilia.

**Study Contact:** Diondra Howard - howar709@umn.edu

**Principal Investigator:** Jacob Cogan

### IRB

**Number:** STUDY00017896

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.